Original Article
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
N Engl J Med 2005; 353:1114-1123September 15, 2005DOI: 10.1056/NEJMoa050524
- Abstract
Background
A substantial number of patients with rheumatoid arthritis have an inadequate or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a randomized, double-blind, phase 3 trial to evaluate the efficacy and safety of abatacept, a selective costimulation modulator, in patients with active rheumatoid arthritis and an inadequate response to at least three months of anti–TNF-α therapy.
Methods
Patients with active rheumatoid arthritis and an inadequate response to anti–TNF-α therapy were randomly assigned in a 2:1 ratio to receive abatacept or placebo on days 1, 15, and 29 and every 28 days thereafter for 6 months, in addition to at least one disease-modifying antirheumatic drug. Patients discontinued anti–TNF-α therapy before randomization. The rates of American College of Rheumatology (ACR) 20 responses (indicating a clinical improvement of 20 percent or greater) and improvement in functional disability, as reflected by scores for the Health Assessment Questionnaire (HAQ) disability index, were assessed.
Results
After six months, the rates of ACR 20 responses were 50.4 percent in the abatacept group and 19.5 percent in the placebo group (P<0.001); the respective rates of ACR 50 and ACR 70 responses were also significantly higher in the abatacept group than in the placebo group (20.3 percent vs. 3.8 percent, P<0.001; and 10.2 percent vs. 1.5 percent, P=0.003). At six months, significantly more patients in the abatacept group than in the placebo group had a clinically meaningful improvement in physical function, as reflected by an improvement from baseline of at least 0.3 in the HAQ disability index (47.3 percent vs. 23.3 percent, P<0.001). The incidence of adverse events and peri-infusional adverse events was 79.5 percent and 5.0 percent, respectively, in the abatacept group and 71.4 percent and 3.0 percent, respectively, in the placebo group. The incidence of serious infections was 2.3 percent in each group.
Conclusions
Abatacept produced significant clinical and functional benefits in patients who had had an inadequate response to anti–TNF-α therapy.
Media in This Article
Figure 1
Enrollment and Outcomes.Figure 2
Signs and Symptoms of Disease.Article Activity
- Article
Rheumatoid arthritis is a chronic disease that leads to inflammation and progressive joint damage.1 Current therapies target the inflammatory consequences of autoimmune activation with the use of disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and biologic DMARDs, which inhibit inflammatory cytokines such as tumor necrosis factor α (TNF-α).2 Despite the efficacy of agents such as TNF-α inhibitors, a substantial proportion of patients have no response,3-5 have an unsustained response,6 or form antibodies against the drugs.7 There are currently no clinically proven treatment options for patients with an inadequate response to anti–TNF-α therapy.
Abatacept is the first in a new class of agents for the treatment of rheumatoid arthritis that selectively modulate the CD80 or CD86–CD28 costimulatory signal required for full T-cell activation.8,9 CD80 or CD86 on the surface of an antigen-presenting cell binds to CD28 on the T cell, facilitating T-cell activation. In the normal sequence of events, the naturally occurring inhibitory molecule cytotoxic T-lymphocyte antigen 4 (CTLA4) is induced on the surface of the T cell. CTLA4 has a markedly greater affinity for CD80 or CD86 than does CD28, thus outcompeting CD28 for CD80 or CD86 binding.10 Abatacept is a recombinant fusion protein comprising the extracellular domain of human CTLA4 and a fragment of the Fc domain of human IgG1,11 which has been modified to prevent complement fixation. Abatacept, like CTLA4, competes with CD28 for CD80 and CD86 binding and thereby can be used to selectively modulate T-cell activation.9
The efficacy of abatacept has been reported in two phase 2 studies.8,12 In patients with active rheumatoid arthritis and an inadequate response to methotrexate, abatacept in combination with methotrexate led to significant improvements in signs and symptoms, physical function, and the quality of life over a period of 12 months.12,13 Given the novel mechanism of action of abatacept and the recognized role of T cells in rheumatoid arthritis, selective modulation of costimulation represents a rational therapeutic approach in patients with an inadequate response to anti–TNF-α therapy. We therefore initiated the Abatacept Trial in Treatment of Anti-TNF Inadequate Responders (ATTAIN), a six-month, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti–TNF-α therapy who were receiving background DMARDs.
Methods
Patients
Eligible patients met the American College of Rheumatology (ACR) criteria for rheumatoid arthritis, were at least 18 years of age, had had rheumatoid arthritis for at least one year,14 and had an inadequate response to anti–TNF-α therapy with etanercept, infliximab, or both at the approved dose after at least three months of treatment. This study was initiated before the use of adalimumab became widespread. Patients who had adverse events while receiving anti–TNF-α therapy but who discontinued treatment primarily because of a lack of efficacy were also eligible.
Two groups of patients were enrolled: those receiving anti–TNF-α therapy at the time of screening (current users) and those who had previously received such therapy (former users). All users were required to stop taking etanercept or infliximab for at least 28 or 60 days, respectively, before undergoing randomization.
At randomization, patients had to have at least 10 swollen joints, at least 12 tender joints, and C-reactive protein levels of at least 1 mg per deciliter (upper limit of the normal range, 0.5). Patients had to have been taking an oral DMARD or anakinra for at least 3 months, and the dose had to have been stable for at least 28 days. Use of oral corticosteroids (no more than 10 mg of prednisone or its equivalent per day) was allowed if the dose had been stable for at least 28 days. Changes in the doses of background DMARDs were not permitted except to avoid adverse effects.
Study Protocol
Patients were randomly assigned in a 2:1 ratio to receive abatacept or placebo and were stratified according to the use of anti–TNF-α therapy at the time of enrollment (former vs. current use). To ensure balanced treatment-group assignments, no more than two thirds of randomized patients were permitted to be either current or former anti–TNF-α users. There was a central randomization system, and the randomization schedule was generated by the drug-management group within Bristol-Myers Squibb. A total of 89 sites participated, and a median of 3 patients were enrolled per site (range, 1 to 16); there was no stratification according to site.
Patients received a fixed dose of abatacept, approximating 10 mg per kilogram of body weight, or placebo; patients weighing less than 60 kg received 500 mg of abatacept, those weighing 60 to 100 kg received 750 mg, and those weighing more than 100 kg received 1000 mg. Study medication was administered in a 30-minute intravenous infusion on days 1, 15, and 29 and every 28 days thereafter, up to and including day 141. The drug was prepared by pharmacists or other qualified personnel who had no interaction with the patients. Medication was administered intravenously in a blinded fashion by qualified personnel. All clinical assessments of response were performed in a blinded fashion by the same trained assessors throughout the study.
This study was approved by the institutional review boards and independent ethics committees at participating sites and was carried out in accordance with the ethics principles of the Declaration of Helsinki. All patients provided written informed consent before randomization. The academic authors had full access to the data and certify the veracity and completeness of the data and the data analysis.
Measures of Clinical Efficacy
There were two primary end points: the proportion of patients with an ACR 20 response and the proportion of patients with an improvement of at least 0.3 from baseline in the Health Assessment Questionnaire (HAQ) disability index (exceeding the minimal clinically important change of 0.2215) at six months. An ACR 20 response indicates a decrease of at least 20 percent in the number of both tender and swollen joints (68 joints were assessed for tenderness, and 66 joints were assessed for swelling) as well as a 20 percent improvement in at least three of the following: the patient's global assessment of disease activity; the patient's assessment of pain; physical function, as assessed by the HAQ disability index; the physician's global assessment of disease activity; and the C-reactive protein level.16
Secondary objectives included a 50 percent and 70 percent improvement in the ACR response (ACR 50 and ACR 70, respectively) at six months. Changes in disease activity were assessed with the use of the Disease Activity Score 28 (DAS28).17,18 Clinical remission was defined by a DAS28 of less than 2.6,19 and a low level of disease activity was defined by a DAS28 of 3.2 or less.20 The mean improvement in physical function at six months was based on the change from baseline in the HAQ disability index. Changes from baseline in the health-related quality of life were assessed by the Medical Outcomes Study 36-Item Short-Form General Health Survey (SF-36)21 at six months. The SF-36 consists of 36 items, 35 of which are aggregated to evaluate eight dimensions of health: physical function, pain, general and mental health, vitality, social function, and physical and emotional health. Scores on the eight subscales were aggregated to derive the physical-component summary score and the mental-component summary score. Scores on each subscale can range from 0 to 10, and the summary scores can range from 0 to 100, with higher scores indicating better health.
Safety Assessments
Patients were monitored for adverse events, serious adverse events, and clinically significant changes in vital signs and laboratory tests. Both the severity of adverse events and their relation to the study treatment were noted by the investigator.
Immunogenicity Testing
The immunogenicity of abatacept was assessed with the use of two validated, direct-format enzyme-linked immunosorbent assays. One assay measured the response to the whole molecule (anti-abatacept assay), whereas the second assay measured the response to the CTLA4 portion alone. Samples were obtained at baseline (day 1); days 29, 85, and 169; and 85 days after the last dose of abatacept.
Statistical Analysis
All efficacy analyses included all randomized patients who received at least one dose of study medication. The statistical power of the study with respect to the two primary end points of the ACR 20 response and the HAQ response was 96 percent and 87 percent, respectively, at a two-sided alpha level of 5 percent, to detect absolute differences of 20 percent and 18 percent, respectively. No interim analyses were planned or conducted. For the primary analyses of the ACR 20 and HAQ responses, the proportion of patients who had a response at six months was summarized according to the treatment group. A two-sided Cochran–Mantel–Haenszel chi-square test (with stratification according to baseline anti–TNF-α use [current or former]) was used to compare response rates in the abatacept group with those in the placebo group at the 0.05 level of significance. For the analyses of ACR 20 and HAQ responses, all patients who discontinued treatment were subsequently considered not to have had a response. The primary and the multiple secondary end points were tested in a prespecified sequence after the use of a closed testing procedure, thus controlling the overall type I error rate at the 0.05 level. All reported P values are two-sided.
Mean changes from baseline in the DAS28, HAQ disability index, and the scores for the eight individual subscales as well as the physical- and mental-component summary scores of the SF-36 were compared between treatment groups with the use of analysis of covariance after adjustment for the baseline assessments. For patients who discontinued treatment, the last observation was carried forward in subsequent analyses.
Safety was evaluated according to the frequency of adverse events, changes in laboratory values, and abnormal clinical findings. P values for safety comparisons were obtained with the use of a chi-square test or, where appropriate, Fisher's exact test.
Results
Randomization and Outcome
From December 10, 2002, to June 2, 2004, 258 patients were randomly assigned to and treated with abatacept and 133 were assigned to and received placebo (Figure 1Figure 1
Enrollment and Outcomes.). A total of 322 patients completed 24 weeks of therapy: 223 (86.4 percent) in the abatacept group and 99 (74.4 percent) in the placebo group. Lack of efficacy (based on the discretion of the patient and the investigator) was the main reason for discontinuation in both groups (5.4 and 20.3 percent, respectively) (Figure 1).Baseline Demographic and Clinical Characteristics
Baseline demographic and clinical characteristics were similar in the two groups (Table 1Table 1
Baseline Characteristics of the Patients.). Patients had active disease at baseline as evidenced by high mean counts of tender and swollen joints, scores for the HAQ disability index, C-reactive protein levels, and the DAS28 (Table 1). The percentages of current and former anti–TNF-α users were similar in the abatacept and placebo groups (38.0 percent and 41.4 percent, respectively; and 62.0 percent and 58.6 percent, respectively).Clinical Efficacy
Improvement in the Signs and Symptoms
At six months, the rate of ACR 20 responses was significantly higher in the abatacept group than in the placebo group (50.4 percent vs. 19.5 percent, P<0.001) (Figure 2AFigure 2
Signs and Symptoms of Disease.). The rates of responses in the abatacept group were significantly higher than those in the placebo group from day 15 onward and progressively increased during the six-month study period (Figure 2B). The rates of ACR 50 and ACR 70 responses were also significantly higher in the abatacept group than in the placebo group at six months (rate of ACR 50 response, 20.3 percent vs. 3.8 percent, P<0.001; rate of ACR 70 response, 10.2 percent vs. 1.5 percent, P=0.003) (Figure 2A). Among both current and former users of anti–TNF-α therapy, the rates of ACR 20 responses were significantly higher in the abatacept group than in the placebo group (P<0.001 for both comparisons).Current users of anti–TNF-α agents had such therapy withdrawn before undergoing randomization. We assessed the changes in C-reactive protein levels and in the numbers of swollen and tender joints in current and former anti–TNF-α users in the placebo group during the study. We found no significant increase in the number of swollen joints (mean joint count, 20 at screening, 21 at randomization, and 17 on day 29 after randomization), tender joints (mean joint count, 29 at screening, 30 at randomization, and 27 on day 29 after randomization), or C-reactive protein levels (data not shown) during the washout period or subsequently.
Rates of remission (as defined by a DAS28 of less than 2.6) at six months were also significantly higher in the abatacept group than in the placebo group (10.0 percent vs. 0.8 percent, P<0.001) (Figure 2C). Furthermore, 17.1 percent of patients in the abatacept group had a low level of disease activity at six months (as defined by a DAS28 of 3.2 or less), as compared with 3.1 percent of patients in the placebo group (P<0.001).
Improvement in Physical Function
At six months, significantly more patients in the abatacept group than in the placebo group had a clinically meaningful improvement in physical function (defined by an improvement in the HAQ disability index of at least 0.3 from baseline) (47.3 percent vs. 23.3 percent, P<0.001) (Figure 3AFigure 3
Physical Function (Panel A) and Health-Related Quality of Life (Panel B) at Six Months.). Significant improvements were achieved by the time of the first measurement on day 15 in the abatacept group, as compared with the placebo group (data not shown). At six months, the abatacept group also had greater mean improvements from baseline in the HAQ disability index (0.45 vs. 0.11, P<0.001).Improvement in Health-Related Quality of Life
As compared with the placebo group, the abatacept group had significantly greater improvements from baseline in scores for all eight physical and mental subscales of the SF-36 (Figure 3B). The improvements in scores for all subscales were considered clinically meaningful (as reflected by an increase of at least 3 points).22 As compared with the placebo group, the abatacept group also had significant improvements in the physical-component and mental-component summary scores (P<0.001 and P<0.01, respectively) (Figure 3B).
Safety
The rates of discontinuation because of adverse events and serious adverse events were low and similar in the abatacept and placebo groups (3.5 percent and 3.8 percent, respectively; and 2.7 percent and 1.5 percent, respectively) (Table 2Table 2
Adverse Events.). The rates of adverse events and serious adverse events were also similar in the abatacept and placebo groups (79.5 percent and 71.4 percent, respectively; and 10.5 percent and 11.3 percent, respectively) (Table 2). The incidence of serious infections (Table 2) was 2.3 percent in both groups, and no unusual or opportunistic infections were seen.Infections were more frequent in the abatacept group than in the placebo group (37.6 percent vs. 32.3 percent, P=0.30), with nasopharyngitis, sinusitis, upper respiratory tract infection, and bronchitis being reported most frequently. Most infections were mild to moderate in intensity. The rates of discontinuation due to infection were 0.8 percent in the abatacept group and 1.5 percent in the placebo group (P=0.61). One patient treated with abatacept died of a myocardial infarction and congestive heart failure. This event was not considered by the investigator to be related to the study drug.
Abatacept treatment did not increase the risk of inducing antinuclear antibodies or anti–double-stranded DNA antibodies. A total of 7.5 percent of patients in the abatacept group and 11.3 percent of patients in the placebo group were negative for antinuclear antibodies at baseline and became positive during the study. The respective values for anti–double-stranded DNA antibodies were 1.7 percent and 9.4 percent.
Acute infusion reactions were more frequent in the abatacept group than in the placebo group (5.0 percent vs. 3.0 percent, P=0.35), with dizziness (1.6 percent vs. 0 percent, P=0.30) and headache (1.2 percent vs. 0.8 percent, P=1.0) being the most commonly reported events. Infusion reactions were usually mild or moderate in intensity. There were no severe or very severe acute infusion reactions in either group.
Immunogenicity
Antibodies against abatacept developed in only 3 of 234 patients (1.3 percent). In one patient, the response was against the immunoglobulin portion of the molecule, and in two patients the responses were against the CTLA4-binding portion of the molecule. All of these responses showed low-level reactivity.
Discussion
The treatment of rheumatoid arthritis has improved in the past decade, owing in part to the more aggressive use of DMARDs and the introduction of TNF-α inhibitors. Despite these improvements, unmet needs remain, especially for patients who have not had an adequate response to TNF-α inhibition.
We evaluated the efficacy and safety of abatacept in patients with active rheumatoid arthritis who had an inadequate clinical response to anti–TNF-α therapy. These patients had long-standing disease, evidence of clinically significant disease activity, and moderate-to-severe disability. We found clinically meaningful and statistically significant improvements in this refractory population. At six months, all primary and secondary outcomes were improved in the abatacept group as compared with the placebo group. Clinical improvements in ACR 20 and HAQ responses were seen at day 15, and the rates increased over the six-month study period. In addition, the efficacy of abatacept was similar regardless of whether patients were receiving anti–TNF-α therapy at the time of screening or had a history of such therapy. Abatacept therapy also induced significant improvements in physical function and scores for all eight subscales of the SF-36.
The incidence of infection was slightly higher in the abatacept group than in the placebo group, but no specific infection was clearly more frequent, and the intensity of infections appeared similar in the two groups. There were no significant differences in the proportions of patients discontinuing treatment as a result of infection or in the incidence of serious infections. There was a low incidence of serious infusion reactions, and abatacept treatment did not appear to increase the incidence of autoimmunity.
Approximately one third of current users of anti–TNF-α therapy (etanercept or infliximab) had a washout period before undergoing randomization. This could have invoked an artificial flare or worsening of disease. However, there was no evidence of such a flare in patients who had a washout period and were randomly assigned to placebo, indicating that these patients were not benefiting from TNF-α inhibition and that the significant improvement observed after randomization to abatacept reflected treatment of active baseline disease.
Abatacept belongs to a new class of selective costimulation modulators. The efficacy of this agent may in part be explained by its novel mechanism of action at the level of the T cell. By modulating events upstream of T-cell activation, abatacept has the potential to affect multiple downstream pathways.23 Our data suggest that, in addition to playing a key role in the activation of naive T cells that orchestrate early disease,1 costimulation continues to play a role in the pathogenesis of established, long-standing disease.
Our results provide evidence that abatacept is clinically efficacious and has an acceptable safety profile in patients with rheumatoid arthritis and an inadequate response to anti–TNF-α therapy. Abatacept may thus represent a potential new treatment for patients with rheumatoid arthritis, including those who have had an inadequate response to anti–TNF-α therapy.
Supported by Bristol-Myers Squibb and a grant (5 M01 RR000070) from the National Center for Research Resources, National Institutes of Health.
Dr. Genovese reports having served as a consultant for Abbott, Amgen, Genentech, and Bristol-Myers Squibb and as a speaker for Abbott and Amgen and receiving grant support from Abbott, Biogen IDEC, Bristol-Myers Squibb, and Human Genome Services. Drs. Becker, Natarajan, Li, Aranda, and Hagerty are employees of Bristol-Myers Squibb and have stock options in the company. Dr. Hagerty is involved in patent licensing with Bristol-Myers Squibb. Dr. Schiff reports having served as a consultant for and receiving grant support from Bristol-Myers Squibb. Dr. Luggen reports having received grant support from Biogen IDEC, Bristol-Myers Squibb, and Genentech. Dr. Sherrer reports having served as a consultant for Abbott, Amgen, and Bristol-Myers Squibb and as a speaker for Abbott, Amgen, and Wyeth and receiving grant support from Abbott, Amgen, Bristol-Myers Squibb, and Genentech. Dr. Kremer reports having received grant support and consulting and speaking fees from Bristol-Myers Squibb. Dr. Birbara reports having served as a speaker for Merck and Pfizer. Dr. Box reports having served as a consultant for Bristol-Myers Squibb. At the time of submission, Dr. Nuamah was an employee of Bristol-Myers Squibb and had stock options in the company. Dr. Dougados reports having served as a speaker for and receiving grant support from Bristol-Myers Squibb.
Source Information
From Stanford University Medical Center, Stanford, Calif. (M.C.G.); Bristol-Myers Squibb, Princeton, N.J. (J.-C.B., K.N., I.N., T.L., R.A., D.T.H.); the Denver Arthritis Clinic, Denver (M.S.); the University of Cincinnati Medical Center, Cincinnati (M.L.); the Center for Rheumatology, Immunology and Arthritis, Fort Lauderdale, Fla. (Y.S.); the Center for Rheumatology and Albany Medical College, Albany, N.Y. (J.K.); the University of Massachusetts Medical School, Worcester (C.B.); Carolina Bone and Joint, Charlotte, N.C. (J.B.); and Rene Descartes University, Service de Rhumatologie B, Paris (M.D.).
Address reprint requests to Dr. Genovese at the Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford University Medical Center, 1000 Welch Rd., Suite 203, Palo Alto, CA 94304, or at genovese@stanford.edu.
- References
References
1
Choy EH ,Panayi GS . Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916
Full Text | Web of Science | Medline2
Smolen JS ,Steiner G . Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-488
CrossRef | Web of Science | Medline3
Weinblatt ME ,Keystone EC ,Furst DE , et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45[Erratum, Arthritis Rheum 2003;48:355, 2004;50:144.]
CrossRef | Web of Science | Medline4
Weinblatt ME ,Kremer JM ,Bankhurst AD , et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-259
Free Full Text | Web of Science | Medline5
Lipsky PE ,van der Heijde DM ,St Clair EW , et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602
Free Full Text | Web of Science | Medline6
Criscione LG ,St Clair EW . Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002;14:204-211
CrossRef | Web of Science | Medline7
Maini R ,St Clair EW ,Breedveld F , et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-1939
CrossRef | Web of Science | Medline8
Moreland LW ,Alten R ,Van den Bosch F , et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470-1479
CrossRef | Web of Science | Medline9
Emery P . The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:673-681
CrossRef | Web of Science | Medline10
Collins AV ,Brodie DW ,Gilbert RJ , et al. The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201-210
CrossRef | Web of Science | Medline11
Linsley PS ,Brady W ,Urnes M ,Grosmaire LS ,Damle NK ,Ledbetter JA . CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569
CrossRef | Web of Science | Medline12
Kremer JM ,Westhovens R ,Leon M , et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-1915
Free Full Text | Web of Science | Medline13
Kremer JM ,Dougados M ,Emery P , et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: 12-month results of a phase IIB, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271
CrossRef | Web of Science | Medline14
Arnett FC ,Edworthy SM ,Bloch DA , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
CrossRef | Web of Science | Medline15
Wells GA ,Tugwell P ,Kraag GR ,Baker PR ,Groh J ,Redelmeier DA . Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-560
Web of Science | Medline16
Felson DT ,Anderson JJ ,Boers M , et al. American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
CrossRef | Web of Science | Medline17
Prevoo ML ,van 't Hof MA ,Kuper HH ,van Leeuwen MA ,van de Putte LB ,van Riel PL . Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
CrossRef | Web of Science | Medline18
Van Riel P. How to use the DAS28 (1). (Accessed August 22, 2005, at http://www.das-score.nl/www.das-score.nl/howto1.htm.)
19
Fransen J ,Creemers MC ,Van Riel PL . Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004;43:1252-1255
CrossRef | Web of Science | Medline20
Vrijhoef HJ ,Diederiks JP ,Spreeuwenberg C ,Van der Linden S . Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:419-422
CrossRef | Web of Science | Medline21
Ware JE Jr ,Sherbourne CD . The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-483
CrossRef | Web of Science | Medline22
Samsa G ,Edelman D ,Rothman ML ,Williams GR ,Lipscomb J ,Matchar D . Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999;15:141-155
CrossRef | Web of Science | Medline23
Weisman M ,Durez P ,Hallegua D ,Nuamah I ,Vratsanos G ,Becker JC . Abatacept (CTLA4Ig; BMS-188667) inhibits T-cell activation and the subsequent activation of inflammatory cell types, as demonstrated by sustained reductions in multiple inflammatory biomarkers. Ann Rheum Dis 2004;63:Suppl 1:i138-i138 abstract.
CrossRef | Web of Science
- Citing Articles (338)
Citing Articles
1
Pavel Horák, Martina Skácelová, Karel Hejduk, Andrea Smržová, Karel Pavelka. (2013) Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic—data from the ATTRA registry. Clinical Rheumatology
2
Peggy Jacques, Filip Van den Bosch. (2013) Emerging therapies for rheumatoid arthritis. Expert Opinion on Emerging Drugs 18:2, 231-244
3
W. Kievit, J. Fransen, M. C. de Waal Malefijt, A. A. den Broeder, P. L. C. M. van Riel. (2013) Treatment changes and improved outcomes in RA: an overview of a large inception cohort from 1989 to 2009. Rheumatology
4
Peter Nash, Sauithree Nayiager, Mark C. Genovese, Alan J. Kivitz, Kurt Oelke, Charles Ludivico, William Palmer, Cristian Rodriguez, Ingrid Delaet, Ayanbola Elegbe, Michael Corbo. (2013) Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. Arthritis Care & Research 65:5, 718-728
5
Taher E. Taher, Hawzheen A. Muhammad, Asad Rahim, Fabian Flores-Borja, Yves Renaudineau, David A. Isenberg, Rizgar A. Mageed. (2013) Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. European Journal of Clinical Investigationn/a-n/a
6
Ryo Hatano, Kei Ohnuma, Junpei Yamamoto, Nam H. Dang, Taketo Yamada, Chikao Morimoto. (2013) Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody. British Journal of Haematologyn/a-n/a
7
M. Schiff. (2013) Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology
8
Satoshi Kubo, Kazuyoshi Saito, Shintaro Hirata, Shunsuke Fukuyo, Kunihiro Yamaoka, Norifumi Sawamukai, Masao Nawata, Shigeru Iwata, Yasushi Mizuno, Yoshiya Tanaka. (2013) Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology
9
Robert M Beardsley, Eric B Suhler, James T Rosenbaum, Phoebe Lin. (2013) Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opinion on Pharmacotherapy 14:4, 411-424
10
Ana C. Ribeiro, Ieda M. Laurindo, Lissiane K. Guedes, Carla G. Saad, Julio C. Moraes, Clóvis A. Silva, Eloisa Bonfa. (2013) Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care & Research 65:3, 476-480
11
Noemi Busquets-Perez, Helena Marzo-Ortega, Paul Emery. (2013) Emerging drugs for axial spondyloarthritis including ankylosing spondylitis. Expert Opinion on Emerging Drugs 18:1, 71-86
12
, Tsutomu Takeuchi, Tsukasa Matsubara, Taisuke Nitobe, Eiichi Suematsu, Syuji Ohta, Shigeru Honjo, Tohru Abe, Ami Yamamoto, Nobuyuki Miyasaka. (2013) Phase II dose–response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Modern Rheumatology 23:2, 226-235
13
Hèctor Corominas, Lucinda Sánchez-Eslava, Guadalupe García, Isabel Padró, Cristina Aimarich, Joana Gonzàlez, Maria Franco, Emilia Mur, Silvia Sanchez, Glòria Roldán, Silvia Iniesta, Montse Sesma, Josefina Martín, Mari Carmen Rodriguez, Maria Rosa Capellan, Coral Gosálvez, Silvia Garcia-Diaz, Encarnación Sáez, Yolanda Luna, Pilar Plana. (2013) Safety Profile of Biological Intravenous Therapy in a Rheumatoid Arthritis Patients Cohort. Clinical Nursing Monitoring (Sebiol Study). Reumatología Clínica (English Edition) 9:2, 80-84
14
Rubén Burgos-Vargas, Luis Jose Catoggio, Claudio Galarza-Maldonado, Kasmir Ostojich, Mario H. Cardiel. (2013) Current therapies in rheumatoid arthritis: A Latin American perspective. Reumatología Clínica (English Edition) 9:2, 106-112
15
Amit D. Parulekar, Jonathan S. Boomer, Brenda M. Patterson, Huiqing Yin-Declue, Christine M. Deppong, Brad S. Wilson, Nizar N. Jarjour, Mario Castro, Jonathan M. Green. (2013) A Randomized Controlled Trial to Evaluate Inhibition of T-Cell Costimulation in Allergen-induced Airway Inflammation. American Journal of Respiratory and Critical Care Medicine 187:5, 494-501
16
Ernest H. Choy, Arthur F. Kavanaugh, Simon A. Jones. (2013) The problem of choice: current biologic agents and future prospects in RA. Nature Reviews Rheumatology
17
Maya H. Buch, Sue Pavitt, Mahesh Parmar, Paul Emery. (2013) Creative trial design in RA: optimizing patient outcomes. Nature Reviews Rheumatology
18
F. Behrens, M. Köhm. (2013) Personalisierte Medizin bei Zytokin-gerichteten Therapien. Zeitschrift für Rheumatologie 72:1, 41-48
19
Gerd R Burmester, Ricardo Blanco, Christina Charles-Schoeman, Jürgen Wollenhaupt, Cristiano Zerbini, Birgitta Benda, David Gruben, Gene Wallenstein, Sriram Krishnaswami, Samuel H Zwillich, Tamas Koncz, Koshika Soma, John Bradley, Charles Mebus. (2013) Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. The Lancet 381:9865, 451-460
20
Cecilia Beatrice Chighizola, Ennio Giulio Favalli, Pier Luigi Meroni. (2013) Novel Mechanisms of Action of the Biologicals in Rheumatic Diseases. Clinical Reviews in Allergy & Immunology
21
Fernando Kemta Lekpa, Valérie Farrenq, Florence Canouï-Poitrine, Muriel Paul, Xavier Chevalier, Rémy Bruckert, Sylvie Bastuji-Garin, Pascal Claudepierre. (2013) Manque d’efficacité de l’abatacept dans le traitement des spondylarthropathies axiales réfractaires aux anti-TNF-α. Revue du Rhumatisme 80:1, 46-49
22
R.J. Maneiro, Eva Salgado, Loreto Carmona, Juan J. Gomez-Reino. (2013) Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Seminars in Arthritis and Rheumatism
23
Peter C. Taylor. Cell-Targeted Biologics and Targets. In: Kelley's Textbook of Rheumatology. Elsevier, 2013:978-1000.
24
James R. O'Dell. Treatment of Rheumatoid Arthritis. In: Kelley's Textbook of Rheumatology. Elsevier, 2013:1137-1160.e4.
25
Emilio Martín Mola, Alejandro Balsa, Víctor Martínez Taboada, Raimon Sanmartí, José Luis Marenco, Federico Navarro Sarabia, Juan Gómez-Reino, José María Álvaro-Gracia, José Andrés Román Ivorra, Leticia Lojo, Chamaida Plasencia, Loreto Carmona. (2013) Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations. Reumatología Clínica (English Edition) 9:1, 5-17
26
Bongi Kim, Jun-Seop Shin, Chung-Gyu Park. (2013) Functional Characteristics of C-terminal Lysine to Cysteine Mutant Form of CTLA-4Ig. Immune Network 13:1, 16
27
Ziv Rosman, Yehuda Shoenfeld, Gisele Zandman-Goddard. (2013) Biologic therapy for autoimmune diseases: an update. BMC Medicine 11:1, 88
28
Chang-Keun Lee. (2013) Long Term Safety and Efficacy of Abatacept in Patients with Rheumatoid Arthritis. Journal of Rheumatic Diseases 20:2, 71
29
M. Schaller, J.-D. Studt, J. Voorberg, J. A. Kremer Hovinga. (2013) Acquired thrombotic thrombocytopenic purpura. Hämostaseologie 33:2, 121-130
30
Jennifer L. Rogers, Donald S. Serafin, Roman G. Timoshchenko, Teresa K. Tarrant. (2012) Cellular Targeting in Autoimmunity. Current Allergy and Asthma Reports 12:6, 495-510
31
David Wojciechowski, Flavio Vincenti. (2012) Belatacept in kidney transplantation. Current Opinion in Organ Transplantation 17:6, 640-647
32
Jagdish R Nair, Steven W Edwards, Robert J Moots. (2012) Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy. Expert Opinion on Biological Therapy 12:12, 1661-1668
33
M. E. Weinblatt, R. Fleischmann, T. W. J. Huizinga, P. Emery, J. Pope, E. M. Massarotti, R. F. van Vollenhoven, J. Wollenhaupt, C. O. Bingham, B. Duncan, N. Goel, O. R. Davies, M. Dougados. (2012) Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 51:12, 2204-2214
34
R. J. Moots, B. Naisbett-Groet. (2012) The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review. Rheumatology 51:12, 2252-2261
35
Glen S. Hazlewood, Cheryl Barnabe, Susan G. Barr, Liam Martin. (2012) Abatacept Use After Failure of Multiple Biologic Agents in Patients With Severe Rheumatoid Arthritis. Journal of Clinical Rheumatology 18:8, 416-418
36
K. S. Upchurch, J. Kay. (2012) Evolution of treatment for rheumatoid arthritis. Rheumatology 51:suppl 6, vi28-vi36
37
Cloé Comarmond, Patrice Cacoub. (2012) Antiphospholipid syndrome: From pathogenesis to novel immunomodulatory therapies. Autoimmunity Reviews
38
Elizabeth Salt, Leslie Crofford. (2012) Rheumatoid arthritis. The Nurse Practitioner 37:11, 16-22
39
Alberta Y. Hoi, Geoffrey O. Littlejohn. (2012) Abatacept in the treatment of lupus. Expert Opinion on Biological Therapy 12:10, 1399-1406
40
Nobunori Takahashi, Toshihisa Kojima, Kenya Terabe, Atsushi Kaneko, Daihei Kida, Yuji Hirano, Takayoshi Fujibayashi, Yuichiro Yabe, Hideki Takagi, Takeshi Oguchi, Hiroyuki Miyake, Takefumi Kato, Naoki Fukaya, Hisato Ishikawa, Masatoshi Hayashi, Seiji Tsuboi, Daizo Kato, Koji Funahashi, Hiroyuki Matsubara, Yosuke Hattori, Masahiro Hanabayashi, Shinya Hirabara, Yutaka Yoshioka, Naoki Ishiguro. (2012) Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients. Modern Rheumatology
41
Chantal Keijzer, Lotte Wieten, Martijn van Herwijnen, Ruurd van der Zee, Willem Van Eden, Femke Broere. (2012) Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions. Expert Opinion on Therapeutic Targets 16:9, 849-857
42
Anna Dastiridou, Christos Kalogeropoulos, Periklis Brazitikos, Chrysanthos Symeonidis, Sofia Androudi. (2012) New biologic-response modifiers in ocular inflammatory disease: beyond anti-TNF treatment. Expert Review of Clinical Pharmacology 5:5, 543-555
43
Noori Kim, Alice B. Gottlieb. (2012) Psoriasis: Ustekinumab and Other Biologics in the Pipeline. Current Dermatology Reports 1:3, 108-114
44
Tsukasa Matsubara, Seizo Yamana, Shigeto Tohma, Tsutomu Takeuchi, Hirobumi Kondo, Hitoshi Kohsaka, Shoichi Ozaki, Hiroshi Hashimoto, Nobuyuki Miyasaka, Ami Yamamoto, Masaki Hiraoka, Tohru Abe. (2012) Tolerability and efficacy of abatacept in Japanese patients with rheumatoid arthritis: a phase I study. Modern Rheumatology
45
P. Emery. (2012) Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology 51:suppl 5, v22-v30
46
John M. Davis, Eric L. Matteson. (2012) My Treatment Approach to Rheumatoid Arthritis. Mayo Clinic Proceedings 87:7, 659-673
47
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Takunari Yoshinaga, Bruce Freundlich, Michio Suzukawa. (2012) Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study. Rheumatology International 32:6, 1617-1624
48
Alan Reynolds, Andrew S Koenig, Eustratios Bananis, Amitabh Singh. (2012) When is switching warranted among biologic therapies in rheumatoid arthritis?. Expert Review of Pharmacoeconomics & Outcomes Research 12:3, 319-333
49
Javier Rueda-Gotor, Miguel A González-Gay, Ricardo Blanco. (2012) Tocilizumab for the treatment of rheumatoid arthritis. Clinical Practice 9:3, 255-268
50
Jie Tang, Cheng Zhou, Zhi-Jun Zhang, Shu-Sen Zheng. (2012) Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. Hepatobiliary & Pancreatic Diseases International 11:2, 125-131
51
Marc R. Kok, Paul P. Tak. (2012) Taking advances from bench to bedside during the last decade. Best Practice & Research Clinical Rheumatology 26:2, 225-236
52
Thao Pham, Hervé Bachelez, Jean-Marie Berthelot, Jacques Blacher, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Cécile Gaujoux-Viala, Vincent Goëb, Laure Gossec, Philippe Goupille, Séverine Guillaume-Czitrom, Eric Hachulla, Thierry Lequerré, Jean-Pierre Marolleau, Valérie Martinez, Charles Masson, Luc Mouthon, Xavier Puéchal, Pascal Richette, Alain Saraux, Thierry Schaeverbeke, Martin Soubrier, Manuelle Viguier, Olivier Vittecoq, Daniel Wendling, Xavier Mariette, Jean Sibilia. (2012) Abatacept therapy and safety management. Joint Bone Spine 79, 3-84
53
Michel Vierboom, Elia Breedveld, Bert A ‘t Hart. (2012) New drug discovery strategies for rheumatoid arthritis: a niche for nonhuman primate models to address systemic complications in inflammatory arthritis. Expert Opinion on Drug Discovery1-11
54
H. G. Haggerty, S. J. Proctor. (2012) Chronic Administration of Belatacept, a T-cell Co-stimulatory Signal Blocker, in Cynomolgus Monkeys. Toxicological Sciences
55
P. P. Tak, P. J. Mease, M. C. Genovese, J. Kremer, B. Haraoui, Y. Tanaka, C. O. Bingham, A. Ashrafzadeh, H. Travers, S. Safa-Leathers, S. Kumar, W. Dummer. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis & Rheumatism 64:2, 360-370
56
Stefano Alivernini, Elisa Gremese, Gianfranco Ferraccioli. Drugs in Arthritis. In: Scientific Basis of Healthcare. Science Publishers, 2012:134-157.
57
Lawrence Steinman, Joan T Merrill, Iain B McInnes, Mark Peakman. (2012) Optimization of current and future therapy for autoimmune diseases. Nature Medicine 18:1, 59-65
58
Hongen Yin, Cuong Q Nguyen, Yuval Samuni, Toshimitsu Uede, Ammon B Peck, John A Chiorini. (2012) Local delivery of AAV2-CTLA4IgG decreases sialadenitis and improves gland function in the C57BL/6.NOD-Aec1Aec2 mouse model of Sjogren's syndrome. Arthritis Research & Therapy 14:1, R40
59
Myong Joo Hong, Wan-Hee Yoo. (2012) Biologic Agents in Rheumatic Diseases. Korean Journal of Medicine 82:5, 549
60
Norihiko Watanabe, Hiroshi Nakajima. (2012) Coinhibitory Molecules in Autoimmune Diseases. Clinical and Developmental Immunology 2012, 1-7
61
James R. O'Dell. Rheumatoid Arthritis. In: Goldman's Cecil Medicine. Elsevier, 2012:1681-1689.
62
Pedro C. Rodriguez, Roberto Torres-Moya, Gil Reyes, Claudino Molinero, Dinorah Prada, Ana M. Lopez, Isabel M. Hernandez, Maria V. Hernandez, Jose P. Martinez, Xochel Hernandez, Angel Casaco, Mayra Ramos, Yisel Avila, Yinet Barrese, Enrique Montero, Patricia Hernandez. (2012) A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Results in Immunology 2, 204-211
63
Mayumi Hasegawa, Yasuhiko Imai, Masaki Hiraoka, Kiyomi Ito, Amit Roy. (2011) Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients. Journal of Pharmacokinetics and Pharmacodynamics 38:6, 803-832
64
Dimitrios A. Pappas, Laura Geraldino-Pardilla, Joan M. Bathon. (2011) Immune modulation of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 25:6, 873-889
65
Sylvie Fabre, Florence Apparailly. (2011) Gene Therapy for Rheumatoid Arthritis. BioDrugs 25:6, 381-391
66
Richard Charles John Campbell, Michael Batley, Anthony Hammond, Fowzia Ibrahim, Gabrielle Kingsley, David L. Scott. (2011) The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis. Clinical Rheumatology
67
Fatima Alnaimat, Paramvir Sidhu, Sujata Sarkar. (2011) T-cell targeted therapies in autoimmune diseases. Drug Development Research 72:7, 585-597
68
P. D. W. Kiely, C. Deighton, J. Dixey, A. J. K. Ostor, . (2011) Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals. Rheumatology
69
M. C. Genovese, A. Covarrubias, G. Leon, E. Mysler, M. Keiserman, R. Valente, P. Nash, J. A. Simon-Campos, W. Porawska, J. Box, C. Legerton, E. Nasonov, P. Durez, R. Aranda, R. Pappu, I. Delaet, J. Teng, R. Alten. (2011) Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis & Rheumatism 63:10, 2854-2864
70
Maya H. Buch, Andrea Rubbert-Roth, Gianfranco Ferraccioli. (2011) To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmunity Reviews
71
E. Turkstra, S.-K. Ng, P.A. Scuffham. (2011) A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Current Medical Research and Opinion 27:10, 1885-1897
72
P. P. Tak. (2011) A personalized medicine approach to biological treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology
73
M. Ishizaki, R. Muromoto, T. Akimoto, Y. Ohshiro, M. Takahashi, Y. Sekine, H. Maeda, K. Shimoda, K. Oritani, T. Matsuda. (2011) Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. International Immunology 23:9, 575-582
74
Tadatsura Koshika, Carol Phelps, Jason Fang, Seung Eun Lee, Minoru Fujita, David Ayares, David K.C. Cooper, Hidetaka Hara. (2011) Relative Efficiency Of Porcine and Human CTLA4-IG in Inhibiting Human CD4+T Cell Responses Costimulated by Porcine and Human B7 Molecules. Immunologyno-no
75
(2011) American College of Rheumatology Clinical Trial Priorities and Design Conference, July 22-23, 2010. Arthritis & Rheumatism 63:8, 2151-2156
76
I.C. Scott, S. Steer, C.M. Lewis, A.P. Cope. (2011) Precipitating and perpetuating factors of rheumatoid arthritis immunopathology – linking the triad of genetic predisposition, environmental risk factors and autoimmunity to disease pathogenesis. Best Practice & Research Clinical Rheumatology 25:4, 447-468
77
Charalampos Papagoras, Alexandros A Drosos. (2011) Abatacept: a biologic immune modulator for rheumatoid arthritis. Expert Opinion on Biological Therapy 11:8, 1113-1129
78
In-Ho Song, Denis Poddubnyy. (2011) New treatment targets in ankylosing spondylitis and other spondyloarthritides. Current Opinion in Rheumatology 23:4, 346-351
79
Jeffrey R. Curtis, Jasvinder A. Singh. (2011) Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics 33:6, 679-707
80
Valentin Brodszky. (2011) A rheumatoid arthritisben alkalmazott biológiai kezelések hatásossága az ACR70-végpont szerint: indirekt összehasonlítás és metaregresszió Bayes-modell alkalmazásával. Orvosi Hetilap 152:23, 919-928
81
Daniel E. Furst, Aileen L. Pangan, Leslie R. Harrold, Hong Chang, George Reed, Joel M. Kremer, Jeffrey D. Greenberg. (2011) Greater likelihood of remission in rheumatoid arthritis patients treated earlier in the disease course: Results from the Consortium of Rheumatology Researchers of North America registry. Arthritis Care & Research 63:6, 856-864
82
David Wojciechowski, Flavio Vincenti. (2011) Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Seminars in Immunology 23:3, 157-164
83
K. Chatzidionysiou, R. F. van Vollenhoven. (2011) When to initiate and discontinue biologic treatments for rheumatoid arthritis?. Journal of Internal Medicine 269:6, 614-625
84
K. Montag, M. Gingold, A. Boers, G. Littlejohn. (2011) Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Internal Medicine Journal 41:6, 450-455
85
Maya H Buch, Paul Emery. (2011) New therapies in the management of rheumatoid arthritis. Current Opinion in Rheumatology 23:3, 245-251
86
Hélène Bour-Jordan, Jonathan H. Esensten, Marc Martinez-Llordella, Cristina Penaranda, Melanie Stumpf, Jeffrey A. Bluestone. (2011) Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunological Reviews 241:1, 180-205
87
LYNN PETUKHOVA, RITA M. CABRAL, JULIAN MACKAY-WIGGAN, RAPHAEL CLYNES, ANGELA M. CHRISTIANO. (2011) The genetics of alopecia areata: What's new and how will it help our patients?. Dermatologic Therapy 24:3, 326-336
88
Scott E. Plevy, Stephan R. Targan. (2011) Future Therapeutic Approaches for Inflammatory Bowel Diseases. Gastroenterology 140:6, 1838-1846
89
Eva Salgado, Juan J Gómez-Reino. (2011) The risk of tuberculosis in patients treated with TNF antagonists. Expert Review of Clinical Immunology 7:3, 329-340
90
K. Chauffier, C. Salliot, F. Berenbaum, J. Sellam. (2011) Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology
91
Ankit Saxena, Smriti Raychaudhuri. Rheumatoid Arthritis. In: Arthritis. CRC Press, 2011:55-74.
92
Philip Mease, Mark C. Genovese, Geoffrey Gladstein, Alan J. Kivitz, Christopher Ritchlin, Paul P. Tak, Jürgen Wollenhaupt, Orna Bahary, Jean-Claude Becker, Sheila Kelly, Leonard Sigal, Julie Teng, Dafna Gladman. (2011) Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis & Rheumatism 63:4, 939-948
93
Spencer T Martin, Eric M Tichy, Steven Gabardi. (2011) Belatacept: A Novel Biologic for Maintenance Immunosuppression After Renal Transplantation. Pharmacotherapy 31:4, 394-407
94
Hisashi Yamanaka, Yoshiya Tanaka, Eisuke Inoue, Daisuke Hoshi, Shigeki Momohara, Kentaro Hanami, Naoki Yunoue, Kazuyoshi Saito, Kouichi Amano, Hideto Kameda, Tsutomu Takeuchi. (2011) Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Modern Rheumatology 21:2, 122-133
95
Henit Yanai, Stephen B Hanauer. (2011) Assessing Response and Loss of Response to Biological Therapies in IBD. The American Journal of Gastroenterology 106:4, 685-698
96
Fernando Kemta Lekpa, Valérie Farrenq, Florence Canouï-Poitrine, Muriel Paul, Xavier Chevalier, Rémy Bruckert, Sylvie Bastuji-Garin, Pascal Claudepierre. (2011) Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition. Joint Bone Spine
97
Sarah C Horton, Maya H Buch. (2011) Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. Clinical Investigation 1:4, 557-573
98
Tracy Li, George Wells, Rene Westhovens, Paul Emery, Jean-Claude Becker, Peter Tugwell. (2011) Improvements in Participation in Usual Daily Activities in Patients with Rheumatoid Arthritis Treated with Abatacept. Value in Health 14:2, 361-370
99
Shauna Culshaw, Iain B. McInnes, Foo Y. Liew. (2011) What can the periodontal community learn from the pathophysiology of rheumatoid arthritis?. Journal of Clinical Periodontology 38, 106-113
100
M. Schiff. (2011) Abatacept treatment for rheumatoid arthritis. Rheumatology 50:3, 437-449
101
, Chi Chiu Mok, Lai Shan Tam, Tak Hin Chan, Gavin K. W. Lee, Edmund K. M. Li. (2011) Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clinical Rheumatology 30:3, 303-312
102
L. Campbell, C. Chen, S. S. Bhagat, R. A. Parker, A. J. K. Ostor. (2011) Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 50:3, 552-562
103
Maria W. Greenwald, William J. Shergy, Jeffrey L. Kaine, Marianne T. Sweetser, Kye Gilder, Matthew D. Linnik. (2011) Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial. Arthritis & Rheumatism 63:3, 622-632
104
Toshi A. Furukawa, Tatsuo Akechi, Stefan Wagenpfeil, Stefan Leucht. (2011) Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. Schizophrenia Research 126:1-3, 212-219
105
Jasvinder A Singh, George A Wells, Robin Christensen, Elizabeth Tanjong Ghogomu, Lara Maxwell, John K MacDonald, Graziella Filippini, Nicole Skoetz, Damian K Francis, Luciane C Lopes, Gordon H Guyatt, Jochen Schmitt, Loredana La Mantia, Tobias Weberschock, Juliana F Roos, Hendrik Siebert, Sarah Hershan, Chris Cameron, Michael PT Lunn, Peter Tugwell, Rachelle Buchbinder, Jasvinder A Singh. Adverse effects of biologics: a network meta-analysis and Cochrane overview. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
106
Pietro A.A. Canetta, Gerald B. Appel. (2011) New and emerging treatments for lupus nephritis. Dialysis & Transplantation 40:2, 67-71
107
Sophia Koo, Francisco M. Marty, Lindsey R. Baden. (2011) Infectious Complications Associated with Immunomodulating Biologic Agents. Hematology/Oncology Clinics of North America 25:1, 117-138
108
Luciana Breda, Marianna Torto, Sara Sanctis, Francesco Chiarelli. (2011) Biologics in children’s autoimmune disorders: efficacy and safety. European Journal of Pediatrics 170:2, 157-167
109
Mark C. Genovese, Arthur Kavanaugh, Michael E. Weinblatt, Charles Peterfy, Julie DiCarlo, Michael L. White, Maryann O'Brien, Elliott B. Grossbard, Daniel B. Magilavy. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis & Rheumatism 63:2, 337-345
110
Javier Rueda, Miguel A González-Gay, Ricardo Blanco. (2011) Tocilizumab for rheumatoid arthritis: results of the Phase III clinical trial program. Clinical Investigation 1:2, 345-354
111
Sarika Ogale, Elena Hitraya, Henry J Henk. (2011) Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskeletal Disorders 12:1, 204
112
Yuichi Kurihara, Takeshi Nakahara, Masutaka Furue. (2011) αVβ3-integrin expression through ERK activation mediates cell attachment and is necessary for production of tumor necrosis factor alpha in monocytic THP-1 cells stimulated by phorbol myristate acetate. Cellular Immunology 270:1, 25-31
113
Jon T. Giles, Joan M. Bathon. Management of rheumatoid arthritis. In: Rheumatology. Elsevier, 2011:955-963.e2.
114
Roshan Dhawale, Larry W. Moreland. T-cell co-stimulation. In: Rheumatology. Elsevier, 2011:557-562.
115
Regina Rendas-Baum, Gene V Wallenstein, Tamas Koncz, Mark Kosinski, Min Yang, John Bradley, Samuel H Zwillich. (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Research & Therapy 13:1, R25
116
N. Gerdes, A. Zirlik. (2011) Co-stimulatory molecules in and beyond co-stimulation – tipping the balance in atherosclerosis?. Thrombosis and Haemostasis 106:5, 804-813
117
Jie Zhang, Ying Shan, George Reed, Joel Kremer, Jeffrey D Greenberg, Scott Baumgartner, Jeffrey R Curtis. (2011) Thresholds in disease activity for switching biologics in ra patients: Experience from a large United States cohort. Arthritis Care & Researchn/a-n/a
118
Ariel Beresniak, Rafael Ariza-Ariza, Jose Francisco Garcia-Llorente, Antonio Ramirez-Arellano, Danielle Dupont. (2011) Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain. International Journal of Inflammation 2011, 1-9
119
Anita Gupta, Elizabeth Hewitt, Charlie Oshinsky. (2011) Biomarkers and immunomodulation as a treatment option for chronic pain conditions. Pain Management 1:1, 81-86
120
Vasileios C. Kyttaris. Biologic Agents in the Treatment of Systemic Lupus Erythematosus. In: Systemic Lupus Erythematosus. Elsevier, 2011:1109-1117.
121
S. Lloyd, S. Bujkiewicz, A. J. Wailoo, A. J. Sutton, D. Scott. (2010) The effectiveness of anti-TNF- therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology 49:12, 2313-2321
122
Nicolino Ruperto, Daniel J. Lovell, Tracy Li, Flavio Sztajnbok, Claudia Goldenstein-Schainberg, Morton Scheinberg, Inmaculada Calvo Penades, Michael Fischbach, Javier Orozco Alcala, Philip J. Hashkes, Christine Hom, Lawrence Jung, Loredana Lepore, Sheila Oliveira, Carol Wallace, Maria Alessio, Pierre Quartier, Elisabetta Cortis, Anne Eberhard, Gabriele Simonini, Irene Lemelle, Elizabeth Candell Chalom, Leonard H. Sigal, Alan Block, Allison Covucci, Marleen Nys, Alberto Martini, Edward H. Giannini. (2010) Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care & Research 62:11, 1542-1551
123
Nathan J. Felix, Anish Suri, Luisa Salter-Cid, Steven G. Nadler, Sheila Gujrathi, Michael Corbo, Richard Aranda. (2010) Targeting lymphocyte co-stimulation: From bench to bedside. Autoimmunity 43:7, 514-525
124
Saurabh Aggarwal. (2010) What's fueling the biotech engine—2009–2010. Nature Biotechnology 28:11, 1165-1171
125
Soo-In Choi, Ernest Brahn. (2010) Rheumatoid arthritis therapy: Advances from bench to bedside. Autoimmunity 43:7, 478-492
126
Aarat M Patel, Larry W Moreland. (2010) Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Review of Clinical Immunology 6:6, 855-866
127
J. T. Merrill, R. Burgos-Vargas, R. Westhovens, A. Chalmers, D. D'Cruz, D. J. Wallace, S. C. Bae, L. Sigal, J.-C. Becker, S. Kelly, K. Raghupathi, T. Li, Y. Peng, M. Kinaszczuk, P. Nash. (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism 62:10, 3077-3087
128
Majed Khraishi, Anthony Russell, Wojciech P. Olszynski. (2010) Safety profile of abatacept in rheumatoid arthritis: A review. Clinical Therapeutics 32:11, 1855-1870
129
Michael Schiff, Coralie Poncet, Manuela Le Bars. (2010) Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. International Journal of Clinical Rheumatology 5:5, 581-591
130
Manfred Kopf, Martin F. Bachmann, Benjamin J. Marsland. (2010) Averting inflammation by targeting the cytokine environment. Nature Reviews Drug Discovery 9:9, 703-718
131
J. Wollenhaupt, K. Krüger. (2010) Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 69:7, 618-625
132
Yusuf Yazici, Ismail Simsek. (2010) Treatment options for rheumatoid arthritis beyond TNF-α inhibitors. Expert Review of Clinical Pharmacology 3:5, 663-666
133
Sofia Ramiro, Astrid M van Tubergen, Robert BM Landewé. (2010) RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Review of Clinical Immunology 6:5, 713-720
134
Alison M. Gizinski, David A. Fox, Sujata Sarkar. (2010) Co-stimulation and T cells as therapeutic targets. Best Practice & Research Clinical Rheumatology 24:4, 463-477
135
Gabriele Simonini, Luca Cantarini, Cecilia Bresci, Monica Lorusso, Mauro Galeazzi, Rolando Cimaz. (2010) Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmunity Reviews 9:10, 674-683
136
Christine M. Deppong, Amit Parulekar, Jonathan S. Boomer, Traci L. Bricker, Jonathan M. Green. (2010) CTLA4-Ig inhibits allergic airway inflammation by a novel CD28-independent, nitric oxide synthase-dependent mechanism. European Journal of Immunology 40:7, 1985-1994
137
Tamsin M. Lindstrom, William H. Robinson. (2010) Biomarkers for rheumatoid arthritis: Making it personal. Scandinavian Journal of Clinical & Laboratory Investigation 70:s242, 79-84
138
Michael Schiff, Louis Bessette. (2010) Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clinical Rheumatology 29:6, 583-591
139
Charalampos Papagoras, Paraskevi V. Voulgari, Alexandros A. Drosos. (2010) Strategies after the failure of the first anti-tumor necrosis factor α agent in rheumatoid arthritis. Autoimmunity Reviews 9:8, 574-582
140
Sophia Koo, Francisco M. Marty, Lindsey R. Baden. (2010) Infectious Complications Associated with Immunomodulating Biologic Agents. Infectious Disease Clinics of North America 24:2, 285-306
141
Nicolino Ruperto, Daniel J. Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A. Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A. Melo-Gomes, Claudia Saad-Magalhães, J. Chavez-Corrales, Christian Huemer, Alan Kivitz, Francisco J. Blanco, Ivan Foeldvari, Michael Hofer, Gerd Horneff, Hans-Iko Huppertz, Chantal Job-Deslandre, Anna Loy, Kirsten Minden, Marilynn Punaro, Alejandro Flores Nunez, Leonard H. Sigal, Alan J. Block, Marleen Nys, Alberto Martini, Edward H. Giannini. (2010) Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis & Rheumatism 62:6, 1792-1802
142
Francesco Zulian, Marta Balzarin, Fernanda Falcini, Giorgia Martini, Maria Alessio, Rolando Cimaz, Luca Cimino, Maria Elisabetta Zannin. (2010) Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care & Research 62:6, 821-825
143
Edith Villeneuve, Boulos Haraoui. (2010) To switch or to change class—the biologic dilemma in rheumatoid arthritis. Nature Reviews Rheumatology 6:5, 301-305
144
Christoph Strehblow, Guenther Haberhauer, Peter Fasching. (2010) Comparison of different biologic agents in patients with rheumatoid arthritis after failure of the first biologic therapy. Wiener Medizinische Wochenschrift 160:9-10, 225-229
145
Maya H Buch. (2010) Sequential use of biologic therapy in rheumatoid arthritis. Current Opinion in Rheumatology 22:3, 321-329
146
Sougata Karmakar, Jonathan Kay, Ellen M. Gravallese. (2010) Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention. Rheumatic Disease Clinics of North America 36:2, 385-404
147
N. Pilat, U. Baranyi, C. Klaus, E. Jaeckel, N. Mpofu, F. Wrba, D. Golshayan, F. Muehlbacher, T. Wekerle. (2010) Treg-Therapy Allows Mixed Chimerism and Transplantation Tolerance Without Cytoreductive Conditioning. American Journal of Transplantation 10:4, 751-762
148
Daniel E. Furst. (2010) The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism 39:5, 327-346
149
A. Saraux, L. Gossec, P. Goupille, B. Bregman, E. Boccard, D. Dupont, A. Beresniak. (2010) Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology 49:4, 733-740
150
T. A. Hallinen, E. J. O. Soini, K. Eklund, K. Puolakka. (2010) Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. Rheumatology 49:4, 767-777
151
Roberta Faccio, Viviana Cremasco. (2010) PLCγ2: where bone and immune cells find their common ground. Annals of the New York Academy of Sciences 1192:1, 124-130
152
Anthony S. Russell, Wojtek P. Olszynski, K. S. Davison, Cheryl Koehn, Boulos Haraoui. (2010) Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy. Clinical Rheumatology 29:3, 233-239
153
Paul Creamer, Sarah Love-Jones. Pain Associated with Rheumatoid Arthritis. In: Evidence-Based Chronic Pain Management. Wiley-Blackwell, 2010:106-120.
154
Sonja Merkesdal, Timm Kirchhoff, Diane Wolka, Gunter Ladinek, Adrian Kielhorn, Andrea Rubbert-Roth. (2010) Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure. The European Journal of Health Economics 11:1, 95-104
155
Jesús Tornero Molina, Raimon Sanmartí Sala, Vicente Rodríguez Valverde, Emilio Martín Mola, José Luis Marenco de la Fuente, Isidoro González Álvaro, Santiago Muñoz Fernández, Juan Gómez-Reino Carnota, Luis Carreño Pérez, Enrique Batlle Gualda, Alejandro Balsa Criado, José Luis Andreu, José María Álvaro-Gracia, Juan Antonio Martínez López, Estíbaliz Loza Santamaría. (2010) Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatología Clínica (English Edition) 6:1, 23-36
156
Sandra V. Navarra, Oscar D. Naidas. Management of Systemic Lupus Erythematosus Renal Disease. In: Targeted Treatment of the Rheumatic Diseases. Elsevier, 2010:108-123.
157
Teresa A Simon, Johan Askling, Diane Lacaille, Jarrod Franklin, Frederick Wolfe, Allison Covucci, Samy Suissa, Marc C Hochberg, . (2010) Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Research & Therapy 12:2, R67
158
Jinhyun Kim, Yeong-Wook Song. (2010) Medical treatment of rheumatoid arthritis (II): current biologic agents and newly developing drugs. Journal of Korean Medical Association 53:10, 880
159
Steven S. Storage, Harsh Agrawal, Daniel E. Furst. (2010) Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis. The Korean Journal of Internal Medicine 25:1, 1
160
William S. Wilke. Rheumatoid Arthritis. In: Current Clinical Medicine. Elsevier, 2010:1152-1157.
161
Larry W. Moreland. (2009) Cytokines as Targets for Anti-inflammatory Agents. Annals of the New York Academy of Sciences 1182:1, 88-96
162
Chris Deighton. (2009) Therapy: What should we do after the failure of a first anti-TNF?. Nature Reviews Rheumatology 5:11, 596-597
163
Lara Maxwell, Jasvinder A Singh, Lara Maxwell. Abatacept for rheumatoid arthritis. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
164
Jasvinder A Singh, Robin Christensen, George A Wells, Maria E Suarez-Almazor, Rachelle Buchbinder, Maria Angeles Lopez-Olivo, Elizabeth Tanjong Ghogomu, Peter Tugwell, Jasvinder A Singh. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
165
Peter C. Taylor, Marc Feldmann. (2009) Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature Reviews Rheumatology 5:10, 578-582
166
Michael T. Nurmohamed. (2009) Newer Biological Agents in the Treatment of Rheumatoid Arthritis. Drugs 69:15, 2035-2043
167
Ronald F. van Vollenhoven. (2009) Treatment of rheumatoid arthritis: state of the art 2009. Nature Reviews Rheumatology 5:10, 531-541
168
Jonathan H. Esensten, David Wofsy, Jeffrey A. Bluestone. (2009) Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nature Reviews Rheumatology 5:10, 560-565
169
Kei Ohnuma, Masahiko Uchiyama, Ryo Hatano, Wataru Takasawa, Yuko Endo, Nam H. Dang, Chikao Morimoto. (2009) Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells. Biochemical and Biophysical Research Communications 386:2, 327-332
170
Lucienne Chatenoud. (2009) Progress towards the clinical use of CD3 monoclonal antibodies in the treatment of autoimmunity. Current Opinion in Organ Transplantation 14:4, 351-356
171
Jasvinder Singh, Kamalpreet Kour, Mahesh B Jayaram, Jasvinder Singh. Acetylcholinesterase inhibitors for schizophrenia. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2009.
172
Josef S Smolen, Jonathan Kay, Mittie K Doyle, Robert Landewé, Eric L Matteson, Jürgen Wollenhaupt, Norman Gaylis, Frederick T Murphy, Jeffrey S Neal, Yiying Zhou, Sudha Visvanathan, Elizabeth C Hsia, Mahboob U Rahman. (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet 374:9685, 210-221
173
E. M. Massarotti. (2009) FAST4WARD: implications for the clinician. International Journal of Clinical Practice 63:7, 986-988
174
Julie A. Carman, Patricia M. Davis, Wen-Pin Yang, Jun Zhu, Han Chang, Aiqing He, Amy Truong, Suzanne J. Suchard, Steven G. Nadler. (2009) Abatacept Does Not Induce Direct Gene Expression Changes in Antigen-Presenting Cells. Journal of Clinical Immunology 29:4, 479-489
175
Suong Tran, Roderick S. Hooker, Daisha J. Cipher, Andreas Reimold. (2009) Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases. Drugs & Aging 26:7, 607-615
176
Laura J. Gibbons, Kimme L. Hyrich. (2009) Biologic Therapy for Rheumatoid Arthritis. BioDrugs 23:2, 111-124
177
Martin Jan Bergman. (2009) Assessing adequate treatment response in patients with rheumatoid arthritis. Clinical Therapeutics 31:6, 1219-1231
178
William J. Shergy. (2009) Selective Costimulation Modulation with Abatacept: A Look at Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis. Seminars in Arthritis and Rheumatism 38:6, 434-443
179
Tamra M. Arnold, Catherine R. Sears, Chadi A. Hage. (2009) Invasive Fungal Infections in the Era of Biologics. Clinics in Chest Medicine 30:2, 279-286
180
Ewa M. Paleolog. (2009) The vasculature in rheumatoid arthritis: cause or consequence?. International Journal of Experimental Pathology 90:3, 249-261
181
Evelyne Vinet, Christian Pineau, Caroline Gordon, Ann E. Clarke, Sasha Bernatsky. (2009) Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis & Rheumatism 61:5, 587-592
182
Lisa M. Maier, David A. Hafler. (2009) Autoimmunity risk alleles in costimulation pathways. Immunological Reviews 229:1, 322-336
183
Thao Pham, Pascal Claudepierre, Arnaud Constantin, Bruno Fautrel, Laure Gossec, Jacques-Éric Gottenberg, Philippe Goupille, Éric Hachulla, Charles Masson, Jacques Morel, Alain Saraux, Thierry Schaeverbeke, Daniel Wendling, Xavier Mariette, Jean Sibilia. (2009) Abatacept therapy and safety management. Joint Bone Spine 76, S3-S55
184
Vincent Goëb, Maya H Buch, Edward M Vital, Paul Emery. (2009) Costimulation blockade in rheumatic diseases: where we are?. Current Opinion in Rheumatology 21:3, 244-250
185
Peter S. Linsley, Steven G. Nadler. (2009) The clinical utility of inhibiting CD28-mediated costimulation. Immunological Reviews 229:1, 307-321
186
Alejandro Díaz-Borjón. (2009) Guidelines for the Use of Conventional and Newer Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis. Drugs & Aging 26:4, 273-293
187
Gerrit J Wolbink, Lucien A Aarden, BAC Dijkmans. (2009) Dealing with immunogenicity of biologicals: assessment and clinical relevance. Current Opinion in Rheumatology 21:3, 211-215
188
Toru Mima, Norihiro Nishimoto. (2009) Clinical value of blocking IL-6 receptor. Current Opinion in Rheumatology 21:3, 224-230
189
Clifton O. Bingham, Akgun Ince, Boulos Haraoui, Edward C. Keystone, Yun Chon, Scott Baumgartner. (2009) Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Current Medical Research and Opinion 25:5, 1131-1142
190
Austin Vaz, Jeffrey Lisse, Warren Rizzo, Salvatore Albani. (2009) Discussion: DMARDs and biologic therapies in the management of inflammatory joint diseases. Expert Review of Clinical Immunology 5:3, 291-299
191
Anthony Russell, Ariel Beresniak, Louis Bessette, Boulos Haraoui, Proton Rahman, Carter Thorne, Ross Maclean, Danielle Dupont. (2009) Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clinical Rheumatology 28:4, 403-412
192
Riku Korhonen, Eeva Moilanen. (2009) Abatacept, a Novel CD80/86-CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis. Basic & Clinical Pharmacology & Toxicology 104:4, 276-284
193
Sundeep Kumar Upadhyaya. (2009) New And Emerging Therapies For Rheumatoid Arthritis. Apollo Medicine 6:1, 51-54
194
Ying Ma, Bi-rong Lin, Bei Lin, Sheng Hou, Wei-zhu Qian, Jing Li, Min Tan, Jian Ma, Bo-hua Li, Hao Wang, Ai-dong Wen, Ya-jun Guo. (2009) Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacologica Sinica 30:3, 364-371
195
Laura B Hughes, Maria I Danila, S Louis Bridges. (2009) Recent advances in personalizing rheumatoid arthritis therapy and management. Personalized Medicine 6:2, 159-170
196
Roy M. Fleischmann. (2009) Safety of Biologic Therapy in Rheumatoid Arthritis and Other Autoimmune Diseases: Focus on Rituximab. Seminars in Arthritis and Rheumatism 38:4, 265-280
197
John B. Imboden. (2009) The Immunopathogenesis of Rheumatoid Arthritis. Annual Review of Pathology: Mechanisms of Disease 4:1, 417-434
198
Ernest Choy. (2009) RADIATE: more treatment options for patients with an inadequate response to tumor necrosis factor antagonists. Nature Clinical Practice Rheumatology 5:2, 66-67
199
Christian Dejaco, Christina Duftner, Edith Wipfler, Michael Schirmer. (2009) Neue Option in der Behandlung der rheumatoiden Arthritis: Abatacept, ein selektiver Modulator der T-Zell-Kostimulation. Wiener Medizinische Wochenschrift 159:3-4, 70-75
200
Mark C. Genovese. Treatment of Rheumatoid Arthritis. In: Kelley's Textbook of Rheumatology. Elsevier, 2009:1119-1143.
201
Ricardo Blanco Alonso, Mario Agudo Bilbao. (2009) Inhibition of interleukin 6, a new therapeutic option in rheumatoid arthritis. Reumatolog ía Cl ínica (English Edition) 5:3, 121-127
202
Kazuyoshi SAITO, Yoshiya TANAKA. (2009) New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Japanese Journal of Clinical Immunology 32:3, 149-159
203
Sara Kaprove Penn, Larry W. Moreland. Abatacept. In: Rheumatoid Arthritis. Elsevier, 2009:356-361.
204
Bruno Laganà, Marta Vinciguerra, Raffaele DʼAmelio. (2009) Modulation of T-Cell Co-Stimulation in Rheumatoid Arthritis. Clinical Drug Investigation 29:3, 185-202
205
Nadera J. Sweiss, Linda L. Hushaw. (2009) Biologic Agents for Rheumatoid Arthritis. Journal of Infusion Nursing 32:Supplement, S4-S17
206
Clemens Scheinecker. The Role of T Cells in Rheumatoid Arthritis. In: Rheumatoid Arthritis. Elsevier, 2009:91-96.
207
Richard M. Keating. RHEUMATOID ARTHRITIS. In: Pharmacology and Therapeutics. Elsevier, 2009:1025-1038.
208
Patricia Novas Vidal, Silvia González Díez, Javier Velasco Montes. (2009) Legionella in a patient with rheumatoid arthritis receiving abatacept. Reumatología Clínica (English Edition) 5:5, 214-215
209
Peter C. Taylor. Cell-Targeted Biologics and Emerging Targets: Rituximab, Abatacept, and Other Biologics. In: Kelley's Textbook of Rheumatology. Elsevier, 2009:947-961.
210
Harvinder S. Luthra. Rheumatoid Arthritis. In: Morrey's The Elbow and Its Disorders. Elsevier, 2009:1025-1038.
211
Augusto Posadas, Jeffrey Lisse, Sujata Sarkar. (2009) Abatacept in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 5:1, 9-17
212
Guido Valesini, Manuela Di Franco, Francesca Romana Spinelli, Rossana Scrivo. (2008) Induction of remission in rheumatoid arthritis: criteria and opportunities. Rheumatology International 29:2, 131-139
213
Karla L. Miller, Allen D. Sawitzke, John Doane. (2008) Abatacept and serious respiratory infections in patients with previous lung disease. Clinical Rheumatology 27:12, 1569-1571
214
Barbara Segal, Nelson L. Rhodus, Ketan Patel. (2008) Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 106:6, 778-787
215
Robert Launois, Stéphanie Payet, Nathalie Saidenberg-Kermanac'h, Camille Francesconi, Lionel Riou França, Marie-Christophe Boissier. (2008) Budget impact model of rituximab after failure of one or more TNFα inhibitor therapies in the treatment of rheumatoid arthritis. Joint Bone Spine 75:6, 688-695
216
William Shergy. (2008) Durability of therapeutic response in rheumatoid arthritis: clinical trial experience with abatacept. Future Rheumatology 3:6, 507-516
217
T. Li, G. Wells, R. Westhovens, P. Tugwell. (2008) Validation of a simple activity participation measure for rheumatoid arthritis clinical trials. Rheumatology 48:2, 170-175
218
Andrew J K Östör. (2008) Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. Clinical Rheumatology 27:11, 1343-1353
219
K. Krüger, M. Gaubitz, . (2008) Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis. Zeitschrift für Rheumatologie 67:7, 614-616
220
Theodorus van den Broek, John RP Tesser, Salvatore Albani. (2008) The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care. Expert Opinion on Biological Therapy 8:11, 1773-1785
221
Georg Stummvoll, Iris-Melanie Nöbauer-Huhmann, Klaus Machold, Marcus Köller. (2008) Rheumatoide Arthritis. Wiener klinische Wochenschrift Education 3:3, 135-147
222
Georg Schett, Christian Stach, Jochen Zwerina, Reinhard Voll, Bernhard Manger. (2008) How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis & Rheumatism 58:10, 2936-2948
223
Mary Coughlin. (2008) Improving patient outlook in rheumatoid arthritis: Experience with abatacept. Journal of the American Academy of Nurse Practitioners 20:10, 486-495
224
Viviana Cremasco, Daniel B. Graham, Deborah V. Novack, Wojciech Swat, Roberta Faccio. (2008) Vav/Phospholipase Cγ2-mediated control of a neutrophil-dependent murine model of rheumatoid arthritis. Arthritis & Rheumatism 58:9, 2712-2722
225
James A. Garrity, Eric L. Matteson. (2008) Biologic Response Modifiers for Ophthalmologists. Ophthalmic Plastic & Reconstructive Surgery 24:5, 345-347
226
J. D. Isaacs. (2008) Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future. Rheumatology 47:10, 1461-1468
227
Siba P Raychaudhuri, Smriti Kundu-Raychaudhuri, Kouichi Tamura, Taro Masunaga, Kaori Kubo, Kaori Hanaoka, Wen-Yue Jiang, Leonore A Herzenberg, Leonard A Herzenberg. (2008) FR255734, a Humanized, Fc-Silent, Anti-CD28 Antibody, Improves Psoriasis in the SCID Mouse-Psoriasis Xenograft Model. Journal of Investigative Dermatology 128:8, 1969-1976
228
Nicolino Ruperto, Daniel J Lovell, Pierre Quartier, Eliana Paz, Nadina Rubio-Pérez, Clovis A Silva, Carlos Abud-Mendoza, Ruben Burgos-Vargas, Valeria Gerloni, Jose A Melo-Gomes, Claudia Saad-Magalhães, Flavio Sztajnbok, Claudia Goldenstein-Schainberg, Morton Scheinberg, Immaculada Calvo Penades, Michael Fischbach, Javier Orozco, Philip J Hashkes, Christine Hom, Lawrence Jung, Loredana Lepore, Sheila Oliveira, Carol A Wallace, Leonard H Sigal, Alan J Block, Allison Covucci, Alberto Martini, Edward H Giannini. (2008) Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. The Lancet 372:9636, 383-391
229
Bennett O.V. Shum, Michael S. Rolph, William A. Sewell. (2008) Mechanisms in allergic airway inflammation – lessons from studies in the mouse. Expert Reviews in Molecular Medicine 10,
230
Laurent Peyrin-Biroulet, Pierre Desreumaux, William J Sandborn, Jean-Frédéric Colombel. (2008) Crohn's disease: beyond antagonists of tumour necrosis factor. The Lancet 372:9632, 67-81
231
Yukihiko Aikawa, Kimiko Morimoto, Tetsuya Yamamoto, Hisaaki Chaki, Akira Hashiramoto, Hirokazu Narita, Shuichi Hirono, Shunichi Shiozawa. (2008) Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1. Nature Biotechnology 26:7, 817-823
232
Takeji Umemura, Masao Ota, Kaname Yoshizawa, Yoshihiko Katsuyama, Tetsuya Ichijo, Eiji Tanaka, Kendo Kiyosawa. (2008) Association of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with type 1 autoimmune hepatitis in Japanese. Hepatology Research 38:7, 689-695
233
Michelle L. Harris, Erika Darrah, Gordon K. Lam, Susan J. Bartlett, Jon T. Giles, Audrey V. Grant, Peisong Gao, William W. Scott, Hani El‐Gabalawy, Livia Casciola‐Rosen, Kathleen C. Barnes, Joan M. Bathon, Antony Rosen. (2008) Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis & Rheumatism 58:7, 1958-1967
234
Xavier Bosch, Antonio Guilabert, Gerard Espinosa, Eduard Mirapeix. (2008) Immunotherapy for antineutrophil cytoplasmic antibody–associated vasculitis: challenging the therapeutic status quo?. Trends in Immunology 29:6, 280-289
235
Afton L. Hassett, Tracy Li, Steven Buyske, Shantal V. Savage, Monique A. M. Gignac. (2008) The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study*. Current Medical Research and Opinion 24:5, 1443-1453
236
J. C. Cole, T. Li, P. Lin, R. MacLean, G. V. Wallenstein. (2008) Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. Rheumatology 47:7, 1044-1050
237
Y Shirota, GG Illei, NP Nikolov. (2008) Biologic treatments for systemic rheumatic diseases. Oral Diseases 14:3, 206-216
238
Steven R. Goldring. (2008) Cellular and molecular mechanisms regulating articular bone remodeling in rheumatoid arthritis: Pathology teaches physiology. Current Rheumatology Reports 10:2, 81-83
239
Joel M. Kremer, Harry K. Genant, Larry W. Moreland, Anthony S. Russell, Paul Emery, Carlos Abud-Mendoza, Jacek Szechiński, Tracy Li, Julie Teng, Jean-Claude Becker, René Westhovens. (2008) Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis & Rheumatism 58:4, 953-963
240
Tracy Li, Monique Gignac, George Wells, Sophie Shen, Rene Westhovens. (2008) Decreased external home help use with improved clinical status in rheumatoid arthritis: An exploratory analysis of the Abatacept in Inadequate Responders to Methotrexate (AIM) trial. Clinical Therapeutics 30:4, 734-748
241
D. van der Woude, T.W.J. Huizinga. (2008) Translating basic research into clinical rheumatology. Best Practice & Research Clinical Rheumatology 22:2, 299-310
242
Marcus D Köller. (2008) Targeted therapy in rheumatoid arthritis. Expert Opinion on Drug Discovery 3:3, 329-342
243
M. Shimaoka, E. J. Park. (2008) Advances in understanding sepsis. European Journal of Anaesthesiology 25:Supplement 42, 146-153
244
Flavio Vincenti. (2008) Costimulation blockade in autoimmunity and transplantation. Journal of Allergy and Clinical Immunology 121:2, 299-306
245
J. Claude Bennett. (2008) The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis & Rheumatism 58:S2, S53-S57
246
Anna Nolan, Michael Weiden, Ann Kelly, Yoshihiko Hoshino, Satomi Hoshino, Nehal Mehta, Jeffrey A. Gold. (2008) CD40 and CD80/86 Act Synergistically to Regulate Inflammation and Mortality in Polymicrobial Sepsis. American Journal of Respiratory and Critical Care Medicine 177:3, 301-308
247
Allan D. Kirk. Antibodies and Fusion Proteins. In: Kidney Transplantation. Elsevier, 2008:309-332.
248
Sarang Chitale, Robert Moots. (2008) Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy 8:1, 115-122
249
Joseph R Lutt, Atul Deodhar. (2008) Rheumatoid Arthritis. Drugs 68:5, 591-606
250
Raul M. Torres, John Imboden, Harry W. Schroeder. Antigen receptor genes, gene products, and co-receptors. In: Clinical Immunology. Elsevier, 2008:53-77.
251
Augustine M Manadan, Joel A Block. (2008) Rheumatoid Arthritis: Beyond Tumor Necrosis Factor-α Antagonists, B Cell Depletion, and T Cell Blockade. American Journal of Therapeutics 15:1, 53-58
252
Benjamin Leader, Quentin J. Baca, David E. Golan. (2008) Protein therapeutics: a summary and pharmacological classification. Nature Reviews Drug Discovery 7:1, 21-39
253
Sylvaine You, Sophie Candon, Chantal Kuhn, Jean-François Bach, Lucienne Chatenoud. Chapter 2 CD3 Antibodies as Unique Tools to Restore Self-Tolerance in Established Autoimmunity. Elsevier, 2008:13-37.
254
Daniel B. Drachman. Chapter 8 Therapy of myasthenia gravis. Elsevier, 2008:253-272.
255
Josef S Smolen, Daniel Aletaha, Marcus Koeller, Michael H Weisman, Paul Emery. (2007) New therapies for treatment of rheumatoid arthritis. The Lancet 370:9602, 1861-1874
256
Jennifer K. King, Bevra H. Hahn. (2007) Systemic lupus erythematosus: modern strategies for management – a moving target. Best Practice & Research Clinical Rheumatology 21:6, 971-987
257
Jennifer Reynolds, Kam Shojania, Carlo A Marra. (2007) Abatacept: A Novel Treatment for Moderate-to-Severe Rheumatoid Arthritis. Pharmacotherapy 27:12, 1693-1701
258
Chi Chiu Mok. (2007) Management of systemic lupus erythematosus in Chinese patients. Expert Review of Clinical Immunology 3:6, 925-935
259
A. Roy, D. R. Mould, X.-F. Wang, L. Tay, R. Raymond, M. Pfister. (2007) Modeling and Simulation of Abatacept Exposure and Interleukin-6 Response in Support of Recommended Doses for Rheumatoid Arthritis. The Journal of Clinical Pharmacology 47:11, 1408-1420
260
Joseph A Markenson. (2007) Using the new biologic therapies in rheumatoid arthritis: practical aspects. Future Rheumatology 2:5, 475-483
261
Lisa M Lundquist. (2007) Abatacept: a novel treatment for rheumatoid arthritis. Expert Opinion on Pharmacotherapy 8:14, 2371-2379
262
Polly R. Pine, Betty Chang, Nathan Schoettler, Mona L. Banquerigo, Su Wang, Angela Lau, Feifei Zhao, Elliott B. Grossbard, Donald G. Payan, Ernest Brahn. (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clinical Immunology 124:3, 244-257
263
Steven Yeh, Robert B Nussenblatt, Grace A Levy-Clarke. (2007) Emerging biologics in the treatment of uveitis. Expert Review of Clinical Immunology 3:5, 781-796
264
Lucienne Chatenoud, Jeffrey A. Bluestone. (2007) CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Reviews Immunology 7:8, 622-632
265
Geza P Balint, Peter V Balint. (2007) Tocilizumab: a new form of biological therapy for rheumatoid arthritis. Future Rheumatology 2:4, 361-371
266
Heidemarie Becker, Markus Gaubitz, Wolfram Domschke, Torsten Kucharzik. (2007) Treatment of arthralgias and spondyloarthropathy associated with inflammatory bowel disease. Future Rheumatology 2:4, 423-431
267
Adam Reinhardt, Raphael Hirsch. (2007) Gene therapy for rheumatoid arthritis. Future Rheumatology 2:4, 403-413
268
Carolyn L. Bigbee, Daryl G. Gonchoroff, George Vratsanos, Steven G. Nadler, Helen G. Haggerty, JoAnne L. Flynn. (2007) Abatacept treatment does not exacerbate chronicMycobacterium tuberculosis infection in mice. Arthritis & Rheumatism 56:8, 2557-2565
269
Iain B. McInnes, Georg Schett. (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 7:6, 429-442
270
Amit Golding, Uzma J. Haque, Jon T. Giles. (2007) Rheumatoid Arthritis and Reproduction. Rheumatic Disease Clinics of North America 33:2, 319-343
271
Axel Finckh, Adrian Ciurea, Laure Brulhart, Diego Kyburz, Burkhard Möller, Silvia Dehler, Sylvie Revaz, Jean Dudler, Cem Gabay, . (2007) B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents. Arthritis & Rheumatism 56:5, 1417-1423
272
Myew-Ling Toh, Pierre Miossec. (2007) The role of T cells in rheumatoid arthritis: new subsets and new targets. Current Opinion in Rheumatology 19:3, 284-288
273
M Asif A Siddiqui. (2007) The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence. Current Opinion in Rheumatology 19:3, 308-313
274
Bryan S Clay, Anne I Sperling. (2007) T-cell costimulation blockade in immunologic diseases: role of CD28 family members. Expert Review of Clinical Immunology 3:3, 383-393
275
Maya H. Buch, Sarah J. Bingham, Victoria Bejarano, Domini Bryer, Jo White, Paul Emery, Richard Reece, Mark Quinn. (2007) Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis & Rheumatism 57:3, 448-453
276
Cédric Lukas, Bernard Combe, Jacques Morel. (2007) Rheumatoid arthritis and the evolution of therapy: from symptomatic to bench-to-bedside biological drugs. Future Rheumatology 2:2, 143-152
277
Allen Anandarajah. (2007) Advances in the treatment of rheumatoid arthritis and the spondyloarthropathies. Future Rheumatology 2:2, 133-138
278
Christine Barr. (2007) A Nursing Guide to Infusion Therapy with Abatacept for the Treatment of Rheumatoid Arthritis. Journal of Infusion Nursing 30:2, 96-104
279
D. J. Todd, K. H. Costenbader, M. E. Weinblatt. (2007) Abatacept in the treatment of rheumatoid arthritis. International Journal of Clinical Practice 61:3, 494-500
280
Lisa Lundquist. (2007) Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis. Advances in Therapy 24:2, 333-345
281
Flavio Vincenti, Michael Luggen. (2007) T Cell Costimulation: A Rational Target in the Therapeutic Armamentarium for Autoimmune Diseases and Transplantation. Annual Review of Medicine 58:1, 347-358
282
Philip L. De Jager, David A. Hafler. (2007) New Therapeutic Approaches for Multiple Sclerosis. Annual Review of Medicine 58:1, 417-432
283
Sophia Khan, Elizabeth Justice, Paresh Jobanputra. (2007) Adverse reactions and safety of newer disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis. Adverse Drug Reaction Bulletin &NA;:242, 927-930
284
Daniel Muller. Rheumatoid Arthritis. In: Integrative Medicine. Elsevier, 2007:531-539.
285
Ines Pree, Nina Pilat, Thomas Wekerle. (2007) Recent Progress in Tolerance Induction through Mixed Chimerism. International Archives of Allergy and Immunology 144:3, 254-266
286
Vibeke Strand, Robert Kimberly, John D. Isaacs. (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nature Reviews Drug Discovery 6:1, 75-92
287
Eric H Liu, Richard M Siegel, David M Harlan, John J O'Shea. (2007) T cell–directed therapies: lessons learned and future prospects. Nature Immunology 8:1, 25-30
288
Harrison S. Pollinger, Justin M. Burns, Vince P. Casingal, Paul F. Gores. Current immunosuppressive drugs and clinical use. In: Cellular Transplantation. Elsevier, 2007:13-28.
289
J. Smolen, D. Aletaha. (2007) The burden of rheumatoid arthritis and access to treatment: a medical overview. The European Journal of Health Economics 8:S2, 39
290
Bruce E. Sands. (2007) Inflammatory bowel disease: past, present, and future. Journal of Gastroenterology 42:1, 16-25
291
Shridhar Hegde, Michelle Schmidt. Chapter 32 To Market, To Market – 2006. Elsevier, 2007:505-554.
292
Sarah TA Roord, Berent J Prakken, Salvatore Albani. (2006) Present and future of combination therapy of autoimmune diseases. Future Rheumatology 1:6, 649-655
293
Shouvik Dass, Edward M Vital, Paul Emery. (2006) Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis. Expert Opinion on Pharmacotherapy 7:18, 2559-2570
294
Eric M Ruderman, Richard M Pope. (2006) Drug Insight: abatacept for the treatment of rheumatoid arthritis. Nature Clinical Practice Rheumatology 2:12, 654-660
295
Lucienne Chatenoud. (2006) Immune therapies of autoimmune diseases: are we approaching a real cure?. Current Opinion in Immunology 18:6, 710-717
296
Arthur Barrie, Scott Plevy. (2006) Treatment of Immune-Mediated Extraintestinal Manifestations of Inflammatory Bowel Disease with Infliximab. Gastroenterology Clinics of North America 35:4, 883-893
297
Paraskevi V Voulgari, Alexandros A Drosos. (2006) Adalimumab for rheumatoid arthritis. Expert Opinion on Biological Therapy 6:12, 1349-1360
298
Edward M Vital, Paul Emery. (2006) Abatacept in the treatment of rheumatoid arthritis. Therapeutics and Clinical Risk Management 2:4, 365-375
299
ROY M. FLEISCHMANN. (2006) Comparison of the Efficacy of Biologic Therapy for Rheumatoid Arthritis: Can the Clinical Trials Be Accurately Compared?. Rheumatic Disease Clinics of North America 32, 21-28
300
J.-H. Yen. (2006) Treatment of early rheumatoid arthritis in developing countries. Biologics or disease-modifying anti-rheumatic drugs?. Biomedicine & Pharmacotherapy 60:10, 688-692
301
A.I. Snchez Atrio, A. Prez Gmez, E. Cuende Quintana, A. Turrin Nieves. (2006) Aspectos actuales y perspectivas de futuro del tratamiento de la artritis reumatoide. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 9:69, 4436-4442
302
Adriana H Tremoulet, Salvatore Albani. (2006) Novel therapies for rheumatoid arthritis. Expert Opinion on Investigational Drugs 15:11, 1427-1441
303
Anna Nogid, David Q. Pham. (2006) Role of abatacept in the management of rheumatoid arthritis. Clinical Therapeutics 28:11, 1764-1778
304
Evange Romas, Matthew T. Gillespie. (2006) Inflammation-Induced Bone Loss: Can it Be Prevented?. Rheumatic Disease Clinics of North America 32:4, 759-773
305
Linda Leff. (2006) Emerging New Therapies in Rheumatoid Arthritis. Journal of Infusion Nursing 29:6, 326-337
306
Neill M. MacKenzie. (2006) New therapeutics that treat rheumatoid arthritis by blocking T-cell activation. Drug Discovery Today 11:19-20, 952-956
307
Ferdy J. Lejeune. (2006) Editorial: anticytotoxic T lymphocyte-associated antigen 4 treatment ??? can melanoma be cured at the expense of autoimmune disorders?. Melanoma Research 16:5, 377-378
308
M Waldman, G B Appel. (2006) Update on the treatment of lupus nephritis. Kidney International 70:8, 1403-1412
309
Robert W Hoffman. (2006) T-cell-directed therapy in systemic lupus erythematosus. Future Rheumatology 1:5, 597-605
310
Atsuo Nakajima. (2006) Application of cellular gene therapy for rheumatoid arthritis. Modern Rheumatology 16:5, 269-275
311
Karim Raza, Caitriona E. Buckley, Mike Salmon, Christopher D. Buckley. (2006) Treating very early rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 20:5, 849-863
312
M. Weinblatt, B. Combe, A. Covucci, R. Aranda, J. C. Becker, E. Keystone. (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis & Rheumatism 54:9, 2807-2816
313
Hans J.P.M. Koenen, Irma Joosten. (2006) Antigen-Specific Regulatory T-Cell Subsets in Transplantation Tolerance. Human Immunology 67:9, 665-675
314
Chi Chiu MOK. (2006) Biological therapies for rheumatoid arthritis: beyond TNF-α blockade. APLAR Journal of Rheumatology 9:2, 200-205
315
James S.W. Kong, Suzanne S. Teuber, M. Eric Gershwin. (2006) Potential adverse events with biologic response modifiers. Autoimmunity Reviews 5:7, 471-485
316
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2006) Formulary Drug Reviews - Abatacept. Hospital Pharmacy 41:8, 772-782
317
&NA;. (2006) Abatacept: profile report. Drugs & Therapy Perspectives 22:7, 6-8
318
Shouvik Dass, Edward M Vital, Paul Emery. (2006) Rituximab: B-cell depletion therapy for the treatment of rheumatoid arthritis. Future Rheumatology 1:3, 293-302
319
Scott D. Gray-Owen, Richard S. Blumberg. (2006) CEACAM1: contact-dependent control of immunity. Nature Reviews Immunology 6:6, 433-446
320
Lyndell Lim, Eric B Suhler, Justine R Smith. (2006) Biologic therapies for inflammatory eye disease. Clinical and Experimental Ophthalmology 34:4, 365-374
321
Margrit Wiesendanger, Anfisa Stanevsky, Susan Kovsky, Betty Diamond. (2006) Novel therapeutics for systemic lupus erythematosus. Current Opinion in Rheumatology 18:3, 227-235
322
Eric F. Morand, Michelle Leech, Jürgen Bernhagen. (2006) MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis. Nature Reviews Drug Discovery 5:5, 399-411
323
Jonathan C. W. Edwards, Geraldine Cambridge. (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Reviews Immunology 6:5, 394-403
324
Roy Fleischmann. (2006) Anakinra in the treatment of rheumatic disease. Expert Review of Clinical Immunology 2:3, 331-340
325
Cornelia M Weyand, Jörg J Goronzy. (2006) T-cell-targeted therapies in rheumatoid arthritis. Nature Clinical Practice Rheumatology 2:4, 201-210
326
Carol A. Wallace. (2006) Current management of juvenile idiopathic arthritis. Best Practice & Research Clinical Rheumatology 20:2, 279-300
327
Peter C Taylor. (2006) Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?. Nature Clinical Practice Rheumatology 2:3, 128-129
328
Larry Moreland, Guy Bate, Peter Kirkpatrick. (2006) Abatacept. Nature Reviews Drug Discovery 5:3, 185-186
329
Benazir Saleem, Sarah Mackie, Paul Emery. (2006) Infliximab for rheumatoid arthritis. Expert Review of Clinical Immunology 2:2, 193-207
330
Christine Savage, E. William St. Clair. (2006) New Therapeutics in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America 32:1, 57-74
331
Mary Anne Dooley, Ellen M. Ginzler. (2006) Newer Therapeutic Approaches for Systemic Lupus Erythematosus: Immunosuppressive Agents. Rheumatic Disease Clinics of North America 32:1, 91-102
332
René Westhovens. (2006) Abatacept: the first-in-class costimulation blocker for the treatment of rheumatoid arthritis. Future Rheumatology 1:1, 15-22
333
B THIERS. (2006) Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α InhibitionGenovese MC, Becker J-C, Schiff M, et al (Stanford Univ, Calif; Bristol-Myers Squibb, Priceton, NJ; Denver Arthritis Clinic, Denver; et al) N Engl J Med 353:1114–1123, 2005§. Yearbook of Dermatology and Dermatologic Surgery 2006, 193-194
334
M PILLINGER. (2006) Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor-α InhibitionGenovese MC, Becker J-C, Schiff M, et al (Stanford Univ, Calif; Bristol-Myers Squibb, Princeton, NJ; Denver Arthritis Clinic; et al) N Engl J Med 353:1114–1123, 2005§. Yearbook of Medicine 2006, 15-16
335
Pauline S Hervey, Susan J Keam. (2006) Abatacept. BioDrugs 20:1, 53-61
336
Gary Kunkel, Grant W Cannon. (2006) Leflunomide in the treatment of rheumatoid arthritis. Expert Review of Clinical Immunology 2:1, 17-31
337
Ken Garber. (2005) First-in-class biologic to enter rheumatoid arthritis fray. Nature Biotechnology 23:11, 1323-1324
338
Stefan Schreiber. (2005) Of Mice and Men: What to Learn About Human Inflammatory Bowel Disease From Genetic Analysis of Murine Inflammation. Gastroenterology 129:5, 1782-1784
